Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the FMI Sitagliptin/Metformin FDC Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects

Next Previous
Search
Trial Profile

An Open-Label, Randomized, Two-Period Crossover Definitive Bioequivalence Study With the FMI Sitagliptin/Metformin FDC Tablet and Co-Administration of the Sitagliptin and Metformin Individual Tablets After Consumption of a High-Fat Meal in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Metformin/sitagliptin (Primary) ; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Merck & Co

Most Recent Events

  • 22 Jul 2015 According to ClinicalTrials.gov record treatment pattern and serum sample collection time points (for calculation of AUC) had been changed.
  • 02 Feb 2010 Actual number of patients changed from 60 to 61 as reported by ClinicalTrials.gov.
  • 08 Jul 2009 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top